Latest News on SEPN

Financial News Based On Company


Advertisement
Advertisement

JP Morgan maintains Septerna at Overweight, raises price target to $51 from $48

https://www.tradingview.com/news/tradingview:37719aa8f839d:0-jp-morgan-maintains-septerna-at-overweight-raises-price-target-to-51-from-48/
JP Morgan has reiterated its "Overweight" rating for Septerna (SEPN) and increased its price target to $51 from $48, representing a 6.2% raise. This new price target suggests a potential upside of 29.3% from the stock's closing price on November 18. Other recent analyst actions on Septerna also show "Buy" or "Overweight" ratings with price targets ranging from $60 to $65.

Septerna CFO Gil Labrucherie sells $832,359 in company stock By Investing.com

https://ca.investing.com/news/stock-market-news/septerna-cfo-gil-labrucherie-sells-832359-in-company-stock-93CH-4968428
Septerna CFO Gil Labrucherie sold 20,000 shares of the company's common stock for over $832,000 on November 16, 2026, under a pre-arranged sales plan. Despite a recent 5.8% stock decline, Septerna has shown a 71% return over the past year, and analysts like Guggenheim and Wells Fargo have raised their price targets due to promising pipeline developments.

A trust overseen by Septerna (SEPN) CFO Gil M. Labrucherie sold 20,000 shares under a preset plan.

https://www.stocktitan.net/sec-filings/SEPN/form-4-septerna-inc-insider-trading-activity-3dbca1a4b609.html
Septerna, Inc. CFO Gil M. Labrucherie's trust sold 20,000 shares of common stock on November 16, 2026, across three transactions at weighted-average prices ranging from $41.4754 to $43.00. These sales were conducted under a Rule 10b5-1 sales plan established in July 2026. The filing also detailed Labrucherie's direct holdings, including shares acquired through an Employee Stock Purchase Plan.

Form 4 Septerna Inc: Gil M. Labrucherie (CFO) For: 16 November

https://ca.investing.com/news/stock-market-news/form-4-septerna-inc-gil-m-labrucherie-cfo-for-16-november-93CH-4968432
This article reports on a Form 4 filing for Septerna Inc, specifically detailing an event involving Gil M. Labrucherie, the company's CFO. The filing pertains to activity that occurred on November 16. No specific transaction details are provided beyond the fact of the filing.

Form 4 Septerna Inc: Jeffrey Finer (Director, CEO) For: 12 November

https://ca.investing.com/news/stock-market-news/form-4-septerna-inc-jeffrey-finer-director-ceo-for-12-november-93CH-4962484
This article reports on a Form 4 filing for Septerna Inc, indicating that Jeffrey Finer, who holds roles as Director and CEO, had a transaction on November 12. The filing is specific to Septerna Inc, trading under the ticker SEPN, which experienced a -3.74% change.
Advertisement

Form 4 Septerna Inc: Jeffrey Finer (Director, CEO) For: 12 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-septerna-inc-jeffrey-finer-director-ceo-for-12-november-93CH-5708399
Jeffrey Finer, serving as both Director and CEO of Septerna Inc. (SEPN), executed a Form 4 transaction on November 12th. This financial filing indicates an insider transaction, though the specific details of the transaction are not provided in the article. Septerna Inc. saw a minor stock decrease of 2.18% on the day of publication.

Form 4 Septerna, Inc. For: Nov 12 Filed by: Finer Jeffrey

https://www.streetinsider.com/SEC+Filings/Form+4+Septerna%2C+Inc.+For%3A+Nov+12+Filed+by%3A+Finer+Jeffrey/27357767.html
Jeffrey Finer, an officer and director of Septerna, Inc. (SEPN), filed a Form 4 detailing transactions on November 12, 2026. The filing indicates the exercise of stock options to acquire 18,500 shares at $2.76 per share, followed by multiple sales of common stock at weighted average prices ranging from $42.0888 to $46.1631, conducted under a Rule 10b5-1 sales plan. After these transactions, Finer beneficially owned 833,909 shares of common stock and 378,712 derivative securities.

After a $2.76 option exercise, Septerna (SEPN) CEO sells 18,500 shares under a trading plan.

https://www.stocktitan.net/sec-filings/SEPN/form-4-septerna-inc-insider-trading-activity-2a62acaa8ea0.html
Jeffrey Finer, CEO of Septerna, Inc. (SEPN), exercised options for 18,500 shares at $2.76 per share on November 12, 2026, and subsequently sold all of them in five transactions under a Rule 10b5-1 sales plan. The shares were sold at weighted-average prices ranging from $42.0888 to $46.1631, generating approximately $807,000 in gross proceeds with an estimated pre-tax spread of $756,000. Following these transactions, Finer's reported option balance stands at 378,712 shares.

An officer's trust proposes selling 40,000 Septerna (SEPN) shares.

https://www.stocktitan.net/sec-filings/SEPN/144-septerna-inc-sec-filing-1a929f2b793f.html
A trust associated with Septerna officer Gilbert M. Labrucherie Jr. has proposed selling 40,000 common shares of Septerna (SEPN) with an aggregate market value of $1,704,000. The proposed sale date is November 16, 2026, and the shares were acquired in the open market between February 21 and February 27, 2025. This transaction is being conducted under a Rule 10b5-1 plan adopted on July 22, 2026.

SEPN: SEP-479 and SEP-204 set up key 2027 clinical catalysts

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4639972:0-sepn-sep-479-and-sep-204-set-up-key-2027-clinical-catalysts/
Septerna, Inc. (SEPN) is setting up key clinical catalysts for 2027 with its drug candidates. The company expects a Phase I readout for SEP-479 in Q1 2027, followed by Phase II in H2 2027. Additionally, SEP-204's Phase I trial is planned for Q1 2027, while SEP-631 will be directed towards smaller signal-finding studies.
Advertisement

Form 144 Septerna For: 14 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-septerna-for-14-november-93CH-4958882
This article from Investing.com announces the filing of Form 144 for Septerna, referencing the date November 14th. It also mentions a positive stock performance for SEPN. The content is brief and serves primarily as an alert for this financial filing.

Septerna director Alan Ezekowitz sells $3.93M in SEPN stock By Investing.com

https://ca.investing.com/news/stock-market-news/septerna-director-alan-ezekowitz-sells-393m-in-sepn-stock-93CH-4958161
Alan Ezekowitz, a director at Septerna, Inc. (NASDAQ:SEPN), sold 81,820 shares of common stock for $3.93 million on November 11, 2026. This transaction was part of a Rule 10b5-1 sales plan, and following the sale, Ezekowitz holds 35,600 shares. The stock experienced a 13% drop in the past week but has gained 83% over the last year, with analysts from Guggenheim and Wells Fargo raising their price targets due to optimistic outlooks on Septerna's drug pipeline.

Form 4 Septerna Inc: Alan Ezekowitz (Director) For: 11 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-septerna-inc-alan-ezekowitz-director-for-11-november-93CH-5704284
This article reports on a Form 4 filing for Septerna Inc, detailing a transaction by director Alan Ezekowitz on November 11. Form 4s disclose changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol SEPN and notes a 1.77% change.

Seven planned sales: Septerna (SEPN) director Alan Ezekowitz sells 81,820 shares.

https://www.stocktitan.net/sec-filings/SEPN/form-4-septerna-inc-insider-trading-activity-ecfd0968fb05.html
Septerna director Alan Ezekowitz sold 81,820 shares of common stock on November 11, 2026, across seven transactions. These sales were executed under a Rule 10b5-1 sales plan established on July 13, 2026, with weighted-average prices ranging from $46.0050 to $51.9000 per share. Following these transactions, Ezekowitz's direct holdings in Septerna common stock stand at 35,600 shares.

Septerna director Alan Ezekowitz sells $3.93M in SEPN stock

https://www.investing.com/news/insider-trading-news/septerna-director-alan-ezekowitz-sells-393m-in-sepn-stock-93CH-5026831
Septerna director Alan Ezekowitz sold 81,820 shares of SEPN common stock for over $3.93 million on November 11, 2026, as part of a pre-planned transaction. Following the sale, Ezekowitz directly holds 35,600 shares, and the stock experienced a 13% decline in the week after the transaction, despite significant year-over-year gains. Analyst firms Guggenheim and Wells Fargo recently raised their price targets for Septerna, citing increased confidence in the company's drug pipeline, particularly its oral small molecule PTH replacement, SEP-479.
Advertisement

Form 4 Septerna Inc: Alan Ezekowitz (Director) For: 11 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-septerna-inc-alan-ezekowitz-director-for-11-november-93CH-4958167
This article reports on a Form 4 filing for Septerna Inc, indicating that Director Alan Ezekowitz made a transaction on November 11th. The brief notice highlights insider trading activity related to the company's stock, SEPN.

Form 144 Septerna For: 12 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-septerna-for-12-november-93CH-4954667
This article from Investing.com announces the filing of Form 144 for Septerna on November 12, 2026. Form 144 indicates an intent to sell restricted or controlled securities. The content primarily consists of the title repeated and provides no further details beyond the announcement of the filing.

A shareholder proposes selling 306,645 Septerna (SEPN) shares acquired in its IPO.

https://www.stocktitan.net/sec-filings/SEPN/144-septerna-inc-sec-filing-a877ff742175.html
Samsara BioCapital, a shareholder of Septerna, Inc. (SEPN), has filed a notice for a proposed sale of 306,645 common shares, valued at approximately $14.9 million. These shares were originally acquired by Samsara BioCapital through an IPO purchase from Septerna on October 25, 2024. The proposed sale date is listed as November 12, 2026, with Merrill Lynch as the broker.

A director reported a 100,000-share sale at Septerna (SEPN).

https://www.stocktitan.net/sec-filings/SEPN/144-septerna-inc-sec-filing-47d7d3a0cb4a.html
Septerna director Alan Ezekowitz reported the sale of 100,000 common shares with an aggregate market value of $5,234,000 on November 11, 2026. The shares were acquired through open-market purchases between March 4-7, 2025, and the sale was filed on November 12, 2026, due to a federal holiday preventing earlier submission. This transaction was reported via a Form 144 SEC filing.

Analysts Have Lowered Expectations For Septerna, Inc. (NASDAQ:SEPN) After Its Latest Results

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/news/analysts-have-lowered-expectations-for-septerna-inc-nasdaqse
Septerna, Inc. (NASDAQ:SEPN) recently reported third-quarter results that fell short of analyst expectations, with revenues missing predictions by 9.1% and a larger-than-forecasted statutory loss per share of US$0.57. Following these results, analysts have revised their 2027 forecasts, trimming revenue estimates to US$68.7m and increasing per-share loss expectations to US$2.41, indicating a more negative outlook despite a modest increase in the price target to US$59.22. The company is now expected to see a significant revenue reduction and underperform the wider industry, which is projected to grow.
Advertisement

Septerna Inc stock hits all-time high at 51.54 USD

https://www.investing.com/news/company-news/septerna-inc-stock-hits-alltime-high-at-5154-usd-93CH-5016128
Septerna Inc.'s stock reached an all-time high of $51.54, trading at $51.32, which is just 1% below its 52-week high, and has seen a 180% return over the past year. This surge is attributed to growing investor confidence and positive market sentiment, driven by advancements in the company's drug pipeline, including SEP-479 and SEP-204, which have led to adjusted price targets from several analyst firms. However, InvestingPro analysis suggests the stock may be overvalued.

Septerna, Inc. Stock 12‑Month Price Target Raised to $59.22, Implies 17% Upside

https://www.tradingview.com/news/tradingview:83819a9b71b72:0-septerna-inc-stock-12-month-price-target-raised-to-59-22-implies-17-upside/
Septerna, Inc. (SEPN) has seen its average 12-month price target increase from $58 to $59.22, with forecasts ranging from $48 to $65 per share from 9 analysts. This new target implies a potential upside of approximately 17% based on the November 9 closing price. The consensus rating for the stock remains a "Buy" across all 10 covering analysts.

Septerna Q3FY26 Results: Net loss widens to $26.6M, R&D costs rise

https://scanx.trade/stock-market-news/companies/septerna-q3fy26-results-net-loss-widens-26-6m-r-d-costs-rise/55804368
Septerna Inc. reported a significant net loss of $26.6 million for Q3FY26, a substantial widening from an $8.2 million profit in the prior year, primarily due to soaring research and development expenses which rose to $36.6 million. The company's revenue also declined by 12.16% year-over-year to $18.881 million, missing analyst estimates, and its EPS of $(0.57) fell short of the $(0.45) consensus. Despite these financial setbacks, Septerna highlighted ongoing Phase 1 clinical trials for SEP-479 and the selection of SEP-204 as a development candidate, maintaining a robust liquidity position expected to fund operations into mid-2029.

Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/septerna-highlights-business-progress-and-reports-third-quarter-2026-financial-results/2465688
Septerna, Inc. (Nasdaq: SEPN) announced pipeline progress and financial results for the third quarter ended September 30, 2026. Key milestones include ongoing Phase 1 trials for SEP-479 (PTH1R agonist) with data expected in Q1 2027, and the selection of SEP-204 (TSHR NAM) as a development candidate with a Phase 1 trial planned for Q1 2027. The company reported a cash position of $565.2 million, expected to fund operations into mid-2029, and a net loss of $26.6 million for the quarter.

Septerna Names SEP-204 as Development Candidate for Graves' Disease and Shares Preclinical Data at 2026 ATA Meeting

https://kalkinemedia.com/us/news/announcements/septerna-names-sep-204-as-development-candidate-for-graves-disease-and-shares-preclinical-data-at-2026-ata-meeting
Septerna, Inc. has officially named SEP-204 as its development candidate for Graves' disease and thyroid eye disease (TED), announcing this decision and sharing preclinical data at the 2026 American Thyroid Association Annual Meeting on November 4, 2026. The company also filed a press release and updated its corporate presentation for stakeholders. This advancement marks a significant step in Septerna's efforts to address these autoimmune conditions.
Advertisement

Form 8K Septerna Inc For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-septerna-inc-for-4-november-93CH-4929820
This article announces that Septerna Inc. filed a Form 8K on November 4. The brief piece includes a stock symbol, SEPN, and indicates that the company's stock experienced a 9.57% gain.

Septerna selects SEP-204 for Graves' disease and TED treatment, plans Phase 1 trial in early 2027

https://pluang.com/en/news-feed/septerna-pilih-sep-204-kandidat-pengembangan-penyakit-graves-ted-data-preklinis
Septerna, Inc. has announced SEP-204 as its lead candidate for treating Graves' disease and thyroid eye disease (TED), an oral drug that inhibits the thyroid-stimulating hormone receptor (TSHR). Preclinical results have been promising, showing normalization of thyroid hormone levels and symptom reduction in animal models. The company plans to initiate Phase 1 clinical trials in healthy volunteers in early 2027, potentially offering a novel treatment that targets the root cause of these autoimmune diseases.

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

https://www.manilatimes.net/2026/11/04/tmt-newswire/globenewswire/septerna-announces-selection-of-sep-204-as-development-candidate-for-graves-disease-and-ted-and-reports-preclinical-data-at-the-2026-american-thyroid-association-annual-meeting/2461711
Septerna, Inc. has selected SEP-204 as its lead development candidate for Graves' disease and thyroid eye disease (TED), reporting promising preclinical data. This potent and selective oral small molecule is designed to block TSHR overactivation, with studies showing restoration of normal thyroid hormone levels and reductions in thyroid enlargement in animal models. Septerna plans to initiate a Phase 1 clinical trial in the first quarter of 2027, anticipating once-daily oral dosing for patients.

Form 8K Septerna Inc For: 4 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-septerna-inc-for-4-november-93CH-5678980
The article reports that Septerna Inc. filed a Form 8K on November 4th, 2026. This SEC filing is relevant to investors as indicated by the inclusion of the stock symbol SEPN and its associated price performance. The content provides a concise announcement without further details regarding the specific nature of the 8K filing.

Four fireside chats are scheduled for Septerna management in Boston, New York, London and Miami.

https://www.stocktitan.net/news/SEPN/septerna-to-participate-in-upcoming-investor-pyq3swbqqogg.html
Septerna (Nasdaq: SEPN) announced that its management will participate in four investor conferences before the end of 2026, featuring fireside chats. These events include the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, the Stifel 2026 Healthcare Conference in New York, the UBS Global Biopharma Conference in London, and the 9th Annual Evercore Healthcare Conference in Miami. Live webcasts of each presentation will be available on the company’s investor website and archived for at least 30 days.
Advertisement

Septerna, Inc. (SEPN)

https://milkroad.com/assets/sepn/
Septerna, Inc. (SEPN) is trading at $44.50 USD, up 0.82% today, with a market cap of $2.08B and significant annual revenue growth of 22,375.6%. Key holders include Jim Simons' Renaissance Technologies and Ken Griffin's Citadel Advisors, with the next earnings estimated for November 9, 2026.

Septerna, Inc. Estimates – NASDAQ:SEPN

https://www.tradingview.com/symbols/NASDAQ-SEPN/financials-estimates/
This article provides an overview of Septerna, Inc. (NASDAQ: SEPN) on TradingView, focusing on its financial actuals and analyst estimates. Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time across income statements, balance sheets, and cash flow statements. The platform emphasizes the importance of independent research, stating that the information provided is not investment advice.

Form 4 Septerna Inc: Elizabeth Bhatt (President and COO) For: 15 October

https://ng.investing.com/news/stock-market-news/form-4-septerna-inc-elizabeth-bhatt-president-and-coo-for-15-october-93CH-2744533
This article reports on a Form 4 filing for Septerna Inc, specifically detailing an insider transaction by Elizabeth Bhatt, the company's President and COO, for October 15. Form 4 filings are regulatory documents disclosing changes in ownership of company stock by insiders. The article also provides a brief overview of Septerna Inc's stock performance.

Septerna president and COO Elizabeth Bhatt sells $149,644 in stock

https://www.investing.com/news/insider-trading-news/septerna-president-and-coo-elizabeth-bhatt-sells-149644-in-stock-93CH-4958518
Elizabeth Bhatt, President and COO of Septerna, Inc. (NASDAQ:SEPN), sold 4,000 shares of common stock worth $149,644 on October 15, 2026, as part of a Rule 10b5-1 sales plan. Concurrently, she acquired 4,000 shares by exercising stock options at a price of $6.81 per share. These transactions occurred amidst positive analyst coverage for Septerna, driven by developments in its Phase 1 trial for SEP-479.

Form 4 Septerna Inc: Elizabeth Bhatt (President and COO) For: 15 October

https://uk.investing.com/news/stock-market-news/form-4-septerna-inc-elizabeth-bhatt-president-and-coo-for-15-october-93CH-4918544
This article reports on a Form 4 filing for Septerna Inc, indicating that Elizabeth Bhatt, the President and COO, made a filing related to the company on October 15th. The brief news item includes the company's stock symbol (SEPN) and general market data, but no specific details about the transaction itself.
Advertisement

Septerna president and COO Elizabeth Bhatt sells $149,644 in stock By Investing.com

https://uk.investing.com/news/stock-market-news/septerna-president-and-coo-elizabeth-bhatt-sells-149644-in-stock-93CH-4918536
Elizabeth Bhatt, President and COO of Septerna Inc. (NASDAQ:SEPN), sold 4,000 shares for $149,644 and acquired 4,000 shares through option exercise for $27,240 on October 15, 2026. These transactions occurred under a Rule 10b5-1 plan, with Septerna's stock showing strong performance and analysts recently raising price targets due to positive Phase 1 trial developments for SEP-479.

Form 4 Septerna Inc: Elizabeth Bhatt (President and COO) For: 15 October

https://in.investing.com/news/stock-market-news/form-4-septerna-inc-elizabeth-bhatt-president-and-coo-for-15-october-93CH-5641375
This article reports on a Form 4 filing for Septerna Inc, indicating an insider transaction involving Elizabeth Bhatt, the President and COO, on October 15. The brief news item notes that Septerna Inc's stock symbol is SEPN, which experienced a 6.65% increase. The article provides no further details on the nature of the transaction.

Form 4 Septerna, Inc. For: Oct 15 Filed by: Bhatt Elizabeth

https://www.streetinsider.com/SEC+Filings/Form+4+Septerna%2C+Inc.+For%3A+Oct+15+Filed+by%3A+Bhatt+Elizabeth/27205012.html
Elizabeth Bhatt, President and COO of Septerna, Inc. (SEPN), filed a Form 4 detailing transactions on October 15, 2026. Bhatt acquired 4,000 shares of common stock through exercising stock options at $6.81 per share and subsequently sold a total of 3,999 shares in two separate transactions at weighted average prices of $36.8715 and $37.6142, respectively, as part of a Rule 10b5-1 plan. Following these transactions, Bhatt beneficially owns 174,209 shares of common stock and 58,230 stock options.

After a $6.81 option exercise, Septerna (SEPN) COO sells 4,000 shares under a preset plan.

https://www.stocktitan.net/sec-filings/SEPN/form-4-septerna-inc-insider-trading-activity-7f1510fbc437.html
Elizabeth Bhatt, President and COO of Septerna, Inc. (SEPN), exercised options for 4,000 shares at $6.81 per share and subsequently sold all 4,000 shares on October 15, 2026. The sales were conducted under a Rule 10b5-1 plan adopted a year prior, with the shares sold at weighted average prices of $36.8715 and $37.6142. Following these transactions, Bhatt's option position was 58,230 shares and her common stock holdings were 174,209 shares.

Form 144 Septerna For: 18 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-septerna-for-18-october-93CH-4887184
The article "Form 144 Septerna For: 18 October" from Investing.com announces a Form 144 filing for Septerna. While providing the headline and publication date, the content of the article itself is minimal, primarily serving as a placeholder or a link to further information about the filing. It mentions SEPN with a +3.58% change, indicating some market activity related to the company.
Advertisement

Officer Daniel Long proposes selling 10,001 Septerna (SEPN) common shares.

https://www.stocktitan.net/sec-filings/SEPN/144-septerna-inc-sec-filing-50400dcd6db7.html
Septerna officer Daniel Long has proposed selling 10,001 common shares of SEPN, valued at approximately $391,339.13, with an approximate sale date of October 1, 2026. These shares are to be acquired through stock option exercises over the next three months. The filing also notes two prior 10b5-1 sales by Long: 3,333 shares on September 1, 2026, and 3,334 shares on August 3, 2026.

Septerna Officer Samira Shaikhly Files Form 144 to Sell 12,592 Common Shares

https://kalkinemedia.com/us/news/announcements/septerna-officer-samira-shaikhly-files-form-144-to-sell-12592-common-shares
Septerna officer Samira Shaikhly has filed a Form 144 to sell 12,592 shares of the company's common stock, valued at over $492,000. These shares were acquired through the exercise of stock options on October 1, 2026, and the sale will be conducted on NASDAQ via Morgan Stanley Smith Barney LLC under a Rule 10b5-1 trading plan. This disclosure indicates no prior sales by Shaikhly in the preceding three months and confirms she is unaware of any undisclosed material adverse information about Septerna.

An officer proposes selling 12,592 Septerna (SEPN) shares acquired by exercising stock options.

https://www.stocktitan.net/sec-filings/SEPN/144-septerna-inc-sec-filing-d6b799ce23bc.html
Septerna, Inc. officer Samira Shaikhly has proposed selling 12,592 common shares with an aggregate market value of $492,724.96. These shares were acquired on October 1, 2026, through the exercise of stock options for cash. The proposed sale is being handled by Morgan Stanley Smith Barney LLC and the approximate sale date is October 1, 2026.

SEPN - Long-Term GPCR Platform And Novo Nordisk Collaboration Will Drive Future Value Potential

https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-sepn/septerna/xhx4fcy3-long-term-gpcr-platform-and-novo-nordisk-collaboration-will-drive-future-value-potential
Septerna (SEPN) is seen as undervalued by analysts, who predict significant future value driven by its GPCR platform, lead drug candidates SEP-479 and SEP-631, and a collaboration with Novo Nordisk. Key catalysts include positive Phase 1 data for SEP-479 in hypoparathyroidism and advancements in other pipeline programs. Despite an expected near-term revenue decrease, analysts project long-term profit margin growth and a consensus price target of $54.22, implying a substantial upside from the current share price.

Septerna, Inc. - Common Stock (NQ: SEPN)

https://markets.chroniclejournal.com/observerreporter/quote/news?ChannelType=NEWS&CurrentPage=1&Symbol=NQ%3ASEPN
This article provides recent news headlines for Septerna, Inc. (Nasdaq: SEPN), including analyst coverage initiations with "Overweight" ratings and price targets of $50 and $38 due to the company's innovative GPCR platform and pipeline. It also lists other premarket stock movements and IPO-related news for different companies.
Advertisement

Septerna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?

https://ca.finance.yahoo.com/news/septerna-sepn-heads-healthcare-conferences-141024081.html
Septerna (SEPN) is attending upcoming healthcare conferences, generating investor interest despite recent share price fluctuations. While the company shows strong long-term momentum, its current Price-to-Sales (P/S) ratio of 18.2x is significantly higher than industry averages and its estimated fair value, suggesting it may be overvalued based on future pipeline potential rather than current financials. Investors are advised to critically assess the company's valuation, considering both potential upsides and risks like clinical data disappointments or revenue declines.

Septerna (SEPN) awards CMO 275,000 options at $37.37

https://www.stocktitan.net/sec-filings/SEPN/form-4-septerna-inc-insider-trading-activity-7e0fb7100fa1.html
Septerna, Inc. (SEPN) announced that its Chief Medical Officer, Rajiv Patni, was granted 275,000 stock options on September 8, 2026, with an exercise price of $37.37 per share and an expiration date of September 7, 2036. The options will vest over time, with 25% vesting on August 24, 2027, and the remaining 75% in monthly installments, contingent on his continuous service. This grant resulted in Patni holding 275,000 options for the company.

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/09/11/tmt-newswire/globenewswire/septerna-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635c4/2423000
Septerna, Inc. announced an inducement grant of a non-qualified stock option to purchase up to 275,000 shares of its common stock to its new Chief Medical Officer, Rajiv Patni, M.D. This grant, effective September 8, 2026, was made under the Company's 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $37.37 per share and vests over four years, subject to continuous employment.

Septerna's CMO Rajiv Patni Granted 275,000 Stock Options with 10-Year Expiry

https://kalkinemedia.com/us/news/announcements/septernas-cmo-rajiv-patni-granted-275000-stock-options-with-10-year-expiry
Septerna, Inc.'s Chief Medical Officer, Rajiv Patni, was granted stock options for 275,000 common shares on September 8, 2026. The options have an exercise price of $37.37 per share and will expire on September 7, 2036. The vesting schedule requires continuous service, with 25% vesting in August 2027 and the remaining 75% vesting monthly over 36 months.

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

https://finance.yahoo.com/healthcare/articles/septerna-inc-announces-inducement-grant-200000270.html
Septerna, Inc. announced an inducement grant of a non-qualified stock option to purchase up to 275,000 shares of its common stock to Rajiv Patni, M.D., the new Chief Medical Officer. The grant, effective September 8, 2026, has an exercise price of $37.37 per share and vests over four years, in accordance with Nasdaq Listing Rule 5635(c)(4). Septerna is a clinical-stage biotechnology company focused on GPCR therapies.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement